As shown in Figure 4A, LTBR was identified as a risk factor for PFI in ACC, BRCA, CESC, GBM, KIRC, LGG, PAAD, and UVM patients, while it exhibited a protective effect in OV patients. Here, LTBR is linked to pancreatic adenocarcinoma.